Literature DB >> 11957074

Risk of second malignancies after surgical treatment for early gastric cancer.

Federico Bozzetti1, Giuliano Bonfanti, Luigi Mariani, Rosalba Miceli, Salvatore Andreola.   

Abstract

We evaluated the follow-up of 105 patients who received surgical treatment at our Institute for early gastric cancer (EGC). Median follow-up was 71 months. Operative mortality was 5.7% and the 5-year survival rate was 82.8%, approximately that of an age- and sex- matched Italian population. Overall mortality was assessed with regard to mortality from gastric cancer or other causes. Ten second primary malignancies were identified, and the standardized mortality ratio (1.12; 90% confidence interval [CI] 0.77-1.64) and standardized morbidity ratio (1.50; 90% CI 0.89-2.50) were determined using data from the Tumor Registry of Lombardy. To our knowledge, this is the biggest Western series to measure the risk EGC patients face of developing a second primary tumor. In conclusion, oncologists who follow-up patients surgically treated for EGC, a disease that is much less frequent in Western countries than in Eastern ones, should be aware of the possible occurrence of extragastric primary tumors so that they may plan the appropriate diagnostic investigation when necessary.

Entities:  

Year:  1999        PMID: 11957074     DOI: 10.1007/s101200050024

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  2 in total

1.  Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan.

Authors:  San-Chi Chen; Chia-Jen Liu; Yu-Wen Hu; Chiu-Mei Yeh; Li-Yu Hu; Yen-Po Wang; Yi-Ping Hung; Cheng-Hwai Tzeng; Tzeon-Jye Chiou; Tzeng-Ji Chen; Chung-Jen Teng
Journal:  Gastric Cancer       Date:  2015-03-13       Impact factor: 7.370

2.  Is Colonoscopic Screening Necessary for Patients Younger than 50 Years with Gastric Adenoma or Cancer?

Authors:  Nam Hee Kim; Jung Ho Park; Dong Il Park; Chong Il Sohn; Yoon Suk Jung
Journal:  J Korean Med Sci       Date:  2017-08       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.